In 2022, EBOS completed five acquisitions. Photo: RNZ / Nate McKinnon
Healthcare and animal products company EBOS has announced another record half-year profit, driven by new acquisitions and growth in its healthcare division.
Key numbers for the six months ended December compared with a year ago:
- net profit A$132.2m vs $101.9m ($146m vs $112.48m)
- revenue A$6.15b vs $5.25b ($6.79b vs $2.48b)
- underlying profit A$141.6m vs $109.3m ($156.3m vs $120.64m)
- interim dividend NZ 53c per share vs 47c
Chief executive John Cullity said there was strong organic growth across the group, in addition to the growth from new acquisitions.
In 2022, EBOS completed five acquisitions to expand its medical consumables and medical technology distributions businesses.
"The strength and diversity of our portfolio of businesses is reflected as both our healthcare and animal care segments contributed strongly to the overall result, and we successfully executed our strategy of pursuing both organic and inorganic growth," Cullity said.
Its healthcare division saw underlying profit increase 37.6 percent to $255m.
EBOS said the healthcare segment had strong contributions from each of its community pharmacy TerryWhite Chemmart, institutional healthcare and contract logistics divisions.
Each of its healthcare divisions recorded double-digit gross operating revenue.
The animal care segment saw underlying profit increase by nearly a third to $51m.
It said its Black Hawk and Vitapet brands increased sales by 15.2 percent and 6.3 percent respectively.
The company also increased its margins to relieve pressure from supply side constraints and cost increases.
EBOS said its balance sheet remained strong and well-positioned to pursue further growth opportunities.
It forecast another full year of profitable growth, but did not provide a guidance range.
